顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Maibos CEO Qian Xueming: From molecules to antibody drugs, we work hard on the road to benefit patients

Maibos CEO Qian Xueming: From molecules to antibody drugs, we work hard on the road to benefit patients

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:58
  • Views:

(Summary description)In 2010, Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, embarked on a return trip. After more than two years of preparation, he founded his own b

Maibos CEO Qian Xueming: From molecules to antibody drugs, we work hard on the road to benefit patients

(Summary description)In 2010, Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, embarked on a return trip. After more than two years of preparation, he founded his own b

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:58
  • Views:
Information

In 2010, Dr. Qian Xueming, who has worked for multinational pharmaceutical giant Amgen for more than 12 years, embarked on a return trip. After more than two years of preparation, he founded his own biomedical company, Maibos Bio. With the self-developed new antibody discovery technology, the company has the world's first pH-dependent binding PD-L1 antibody.

 

On February 16, 2018, the US FDA approved Maibos Bio's humanized PD-L1 monoclonal antibody, MSB2311, for clinical trial applications for the treatment of locally advanced or metastatic solid tumors. This is an important milestone for Maibos Bio. Subsequently, the company began to launch MSB2311's first human, open, multi-center, dose escalation and expansion clinical studies.

 

Previously, the FDA has approved multiple PD-L1 and PD-1 antibodies for the treatment of various solid tumors and lymphomas. Compared with the FDA-approved PD-L1 antibody, MSB2311 not only has a unique antigen-binding epitope, but also has a unique pH-dependent binding to the antigen PD-L1, which helps MSB2311 antibody to recover and penetrate in tumor tissues. And enrichment.

 

On May 9, Dr. Xueming Qian introduced to reporters at the 5th anniversary celebration, "MSB2311 has launched Phase 1 clinical trials in the United States. Maibos expects to launch at least one registered clinical trial for product listing in the second half of 2019 At the same time, a number of clinical studies of combined drugs were carried out. In preclinical studies, MSB2311 showed better tumor tissue targeting and penetration ability. This feature makes it possible to show better effectiveness and clinical safety."

 

In addition, Maibos Bio's second project, MSB0254, is also expected to apply for IND in mid-2018, and within the next 18 months, there will be another 1-2 innovative antibodies to complete CMC work and preclinical research and prepare for clinical application.

 

In addition to the last round of investor Eli Lilly Asia Fund and lead investor Sequoia China, the Maibos Bio B round of financing has also added King Star Capital. "Sequoia China is a leader in investment in the healthcare field. We are very honored to receive the support of our company from new investors such as Sequoia China, and we are very grateful for the continued support of Eli Lilly Asia. Our team has made great efforts on the company's innovative product line. This round of financing will ensure that we will advance the MSB2311 project to the critical registered clinical research stage and continue to promote other products into the clinic. "

 

Lu Xiaobo, a partner at Sequoia Capital China Fund, said: "Innovative drugs and innovative biotechnology are one of the important directions for Sequoia China's investment in the field of health care. Maibos Bio's immune tolerance breakthrough technology platform (IMBT) can help discover Antibodies covering a more comprehensive epitope space. The company uses the platform to discover multiple second-generation tumor immunomodulatory antibodies against multiple targets in the tumor microenvironment. These projects can not only be combined with each other clinically, but can also be integrated with the market. There are different combinations of drugs. We look forward to the Maibos team bringing innovative antibody drugs to the market for the benefit of patients around the world. "

 

From molecules to antibody drugs, we work hard on the road to benefit patients! ——This is also Slogan on the cultural wall of Mai Bosi Biological Company, and it is the driving force for Dr. Qian Xueming to lead the team to persist in innovation and hard work.

 

From the original 300 square meters office to the current 2500 square meter R & D center and 12 R & D projects under development, Dr. Qian Xueming only spent 5 years. He hopes that in the next 5 years, there will be better stories for everyone.

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00